| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Sulfacetamide sodium monohydrate targets bacterial dihydropteroate synthase (DHPS), an enzyme involved in folic acid synthesis. It competitively inhibits bacterial para-aminobenzoic acid (PABA), which is required for bacterial folic acid synthesis. The compound blocks the synthesis of dihydrofolic acid with an IC50 of 9.5 μM. It triggers autophagy in T-47D cells via a DAPK-independent pathway.
|
|---|---|
| ln Vitro |
In vitro, Sulfacetamide sodium monohydrate inhibits dihydropteroate synthase with an IC50 of 9.5 μM. It triggers autophagy in T-47D cells via a DAPK-independent pathway. The compound exhibits antibacterial activity against sulfonamide-sensitive Gram-negative and Gram-positive bacteria. It shows anti-proliferative effects on T-47D cells independent of apoptosis and cell cycle arrest.
|
| ln Vivo |
In vivo, Sulfacetamide sodium monohydrate is used topically as an anti-infective agent for skin infections and as an oral agent for urinary tract infections. It has been investigated for the treatment of rosacea and pityriasis versicolor. The compound inhibits microbial growth by blocking folic acid synthesis. It is a bacteriostatic agent active against sulfonamide-sensitive bacteria.
|
| Enzyme Assay |
In vitro enzyme assays for Sulfacetamide sodium monohydrate involve measuring dihydropteroate synthase (DHPS) inhibition. DHPS activity is assessed by monitoring the incorporation of p-aminobenzoic acid into dihydropteroic acid. The compound is added at varying concentrations, and IC50 values are calculated from dose-response curves (IC50 = 9.5 μM). For antibacterial assays, minimum inhibitory concentration (MIC) is determined against various bacterial strains.
|
| Cell Assay |
In vitro cell-based assays for Sulfacetamide sodium monohydrate are conducted in T-47D breast cancer cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Autophagy induction is assessed by measuring LC3-II conversion and autophagosome formation. Anti-proliferative effects are assessed by cell viability assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Sulfacetamide sodium monohydrate in vivo studies are conducted in animal models of skin and urinary tract infections. Animals are treated with the compound via topical application or oral administration. Infection resolution is assessed by bacterial counts. For rosacea and pityriasis versicolor studies, animal models of these conditions are used. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Sulfacetamide sodium monohydrate (MW 254.24 g/mol, C8H11N2NaO4S) is soluble in DMSO at 50 mg/mL and water at 50 mg/mL. It has a logP of 1.868. The compound is stable as a powder at -20°C for 3 years and at 4°C for 2 years. It is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competing with PABA. Pharmacokinetic properties such as absorption and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Sulfacetamide sodium monohydrate is generally well-tolerated as a topical and oral antibiotic. The compound is a sulfonamide with established safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation is available from clinical use data.
|
| Additional Infomation |
Sulfacetamide sodium is an organosodium salt, the monohydrate form of sulfacetyl sodium. It has antibacterial, anti-infective, and EC 2.5.1.15 (dihydropteroate synthase) inhibitory effects. It is an organosodium salt and hydrate. It contains anhydrous sulfacetyl sodium. Sulfacetamide sodium is the sodium salt form of sulfacetyl, a synthetic sulfonylacetamide derivative with antibacterial activity. Sulfacetamide inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid. It has broad-spectrum antibacterial activity and can be used as a topical anti-infective agent for treating skin infections and an oral medication for treating urinary tract infections. (NCI04) A topical antibacterial agent used for burn treatment. See also: sulfacetyl (with active moiety); prednisolone acetate; sodium sulfacetyl (one of the components); sodium sulfacetyl; sulfur (component)... See more...
Sulfacetamide sodium monohydrate is a sulfonamide antibiotic and the sodium salt form of sulfacetamide. It inhibits bacterial dihydropteroate synthase (DHPS) with an IC50 of 9.5 μM, blocking folic acid synthesis by competing with PABA. The compound is active against Streptococci, Staphylococci, and E. coli. It triggers autophagy in T-47D cells and is used to treat skin and urinary tract infections. Its molecular formula is C8H11N2NaO4S with a molecular weight of 254.24 g/mol.All applications are limited to non-human research use. |
| Molecular Formula |
C₈H₁₁N₂NAO₄S
|
|---|---|
| Molecular Weight |
254.24
|
| Exact Mass |
254.033
|
| CAS # |
6209-17-2
|
| Related CAS # |
Sulfacetamide Sodium;127-56-0
|
| PubChem CID |
6419954
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
450.8ºC at 760 mmHg
|
| Flash Point |
226.4ºC
|
| Vapour Pressure |
6.51E-09mmHg at 25°C
|
| LogP |
1.868
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
304
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])([N-]C(C([H])([H])[H])=O)(=O)=O.[Na+].O([H])[H]
|
| InChi Key |
IHCDKJZZFOUARO-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C8H10N2O3S.Na.H2O/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;;/h2-5H,9H2,1H3,(H,10,11);;1H2/q;+1;/p-1
|
| Chemical Name |
sodium;acetyl-(4-aminophenyl)sulfonylazanide;hydrate
|
| Synonyms |
Region; Sulfacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9333 mL | 19.6665 mL | 39.3329 mL | |
| 5 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL | |
| 10 mM | 0.3933 mL | 1.9666 mL | 3.9333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
